Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 12/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112885 | 0.98 | ADORA1 (0.44) | IRAK4ADORA1IRAK1KDM4EMEN1 | |
| SCHEMBL4106545 | 0.89 | ADORA2A (0.46) | IRAK4ADORA1IRAK1ALDH1A1MAPT | |
| SCHEMBL4109415 | 0.89 | DHFR (0.45) | IRAK4ADORA1IRAK1 | |
| SCHEMBL4118619 | 0.89 | IRAK4 (0.42) | IRAK4IRAK1 | |
| SCHEMBL4106600 | 0.89 | IRAK4 (0.42) | IRAK4IRAK1 | |
| SCHEMBL4112210 | 0.89 | IRAK4 (0.47) | IRAK4ADORA1IRAK1KDM4EMEN1 | |
| SCHEMBL4105211 | 0.88 | IRAK4 (0.42) | IRAK4IRAK1 | |
| SCHEMBL4112327 | 0.87 | ADORA2A (0.47) | IRAK4ADORA1MEN1ALDH1A1MAPT | |
| SCHEMBL4115440 | 0.87 | DHFR (0.46) | IRAK4ADORA1IRAK1 | |
| SCHEMBL4112895 | 0.87 | DHFR (0.41) | IRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | claimed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | PRKCA, PRKCG, PRKCH | IRAK4 1916/4885ADORA1 303/4885IRAK1 1856/4885 |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | PRKCA, PRKCG, PRKCH | IRAK4 1916/4885ADORA1 303/4885IRAK1 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.